Company profile
Silence Therapeutics plc
NASDAQ:SLNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Zerlasiran | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04559971 | — | completed | 2020-09-03 | 2021-03-23 | Silence Therapeutics plc | A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers |
| NCT04718844 | phase1 | completed | 2021-04-14 | 2023-05-23 | Silence Therapeutics plc | A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome |
| NCT01808638 | phase1_2 | completed | 2013-03-01 | 2015-08-01 | Silence Therapeutics GmbH | Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) |
| NCT05537571 | phase2 | completed | 2022-12-13 | 2024-01-11 | Silence Therapeutics plc | Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events |
| NCT00938574 | phase1 | completed | 2009-06-01 | 2012-07-01 | Silence Therapeutics GmbH | Study With Atu027 in Patients With Advanced Solid Cancer |
FDA applications (0)
No records yet.